Champions Oncology (CSBR) announced advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions’ service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of services will allow Champions to better serve its clients by offering increased depth through higher complexity spectral analysis. Champions is also pleased to welcome Troy Tremaine, who will lead the commercial strategy for this growing business vertical.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CSBR:
- Champions Oncology price target raised to $8 from $6 at Craig-Hallum
- Champions Oncology Posts Strong Quarterly Revenue Growth
- Champions Oncology (CSBR) Q2 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
